American College of Clinical Pharmacy
      Search      Cart
         

2025 ACCP/ASHP Solid Organ Transplantation Pharmacy Preparatory Review Course: Online Course, ACPE Credit Only


Format to Purchase:
Member Price:
$455.00
Nonmember Price:
$665.00
ASHP members, please visit www.rxcertifications.org to receive member pricing.

Includes:

  • Audio-synchronized slide presentations available online. View slide presentations and listen to faculty as they review each presentation, slide by slide. The audio-synchronized slide presentations include:
    • Downloadable/printable PDFs of presentation slides
    • Downloadable mp3 audio files
    • Downloadable mp4 video files
  • Practice Exam
  • Continuing Pharmacy Education Credit
    • 24.5 hours continuing pharmacy education (CPE) credit available

The ACCP/ASHP Solid Organ Transplantation Pharmacy Preparatory Review Course is ideal for pharmacy professionals who are preparing for the Solid Organ Transplantation Pharmacy Specialty Certification Examination administered by the Board of Pharmacy Specialties (BPS) and for those seeking a self-paced review and refresher of disease states and therapeutics.

Developed by Board Certified Pharmacists and clinical experts, the course content is based on the domains, tasks and knowledge statements outlined in the BPS Solid Organ Transplantation Pharmacy content outline. The course content provides a comprehensive review of the knowledge domains covered in the specialty certification examination. The course uses case-based presentations for application to real-life scenarios, a practice exam along with correct answers, and links to the reference sources, and domains, tasks, and knowledge statements.

Release Date: July 09, 2025
ACPE Deadline: July 09, 2028

Publication Year: 2025
Format: Online Course Package (ACPE credit only)

Technical Requirements:

Contents

Transplant Immunology; Induction and Management of Acute Cellular Rejection - Module 1

Transplant Immunology

Induction and Management of Acute Cellular Rejection

Maintenance of Immunosuppression Part One; Approaches to Prevent and Manage Antibody Development - Module 2

Maintenance of Immunosuppression Part One

Approaches to Prevent and Manage Antibody Development

Kidney Transplantation; Liver Transplantation; Pancreas and Islet Cell Transplantation and Intestinal Transplantation - Module 3

Kidney Transplantation

Liver Transplantation

Pancreas and Islet Cell Transplantation and Intestinal Transplantation

Heart Transplantation; Lung Transplantation; Maintenance of Immunosuppression Part Two - Module 4

Heart Transplantation

Lung Transplantation

Maintenance of Immunosuppression Part Two 

Infection Prevention and Management in Solid Organ Transplant Patients; Prevention and Management of Malignancy in Solid Organ Transplant Patients - Module 5

Infection Prevention and Management in Solid Organ Transplant Patients

Prevention and Management of Malignancy in Solid Organ Transplant Patients

Primary Care of the Solid Organ Transplant Patient; Special Considerations in Pediatric and Geriatric Transplant Populations - Module 6

Primary Care of the Solid Organ Transplant Patient

Special Considerations in Pediatric and Geriatric Transplant Populations

Trial Design and Biostatistics - Module 7

Trial Design and Biostatistics

Continuity of Care and Managing Transitions of Care in the Transplant Patient/Transplant Regulations and Performance Improvement/Transplant Resources, Patient Education and Transplant Study Endpoints - Module 8

Continuity of Care and Managing Transitions of Care in the Transplant Patient

Transplant Regulations and Performance Improvement

Transplant Resources, Patient Education and Transplant Study Endpoints 

Transplant Immunology; Induction and Management of Acute Cellular Rejection - Module 1

*Content Matter Expert

Faculty

Maya Campara, Pharm.D., FCCP, FAST, BCTXP*

Clinical Associate Professor, Pharmacy Practice and Surgery
University of Illinois at Chicago
Chicago, Illinois

Steven Gabardi, Pharm.D., FCCP, FAST, BCPS

Medical Science Liaison – Hepatology
Mallinckrodt Pharmaceuticals
Cambridge, Massachusetts

Maintenance of Immunosuppression Part One; Approaches to Prevent and Manage Antibody Development - Module 2

Faculty

Kimberly Harrison, Pharm.D., BCPS, BCTXP

Heart Transplant Clinical Specialist
Vanderbilt University Medical Center
Nashville, Tennessee

Lyndsey J. Bowman Anger, Pharm.D., FCCP, FAST, BCTXP, BCPS

Pharmacotherapy Specialist, Kidney, and Liver Transplantation Coordinator
Solid Organ Transplant Pharmacist
Tampa General Hospital
Tampa, Florida

Kidney Transplantation; Liver Transplantation; Pancreas and Islet Cell Transplantation and Intestinal Transplantation - Module 3

Faculty

Cassie Stromayer Muran, Pharm.D., BCPS, BCTXP

Abdominal Transplant Clinical Pharmacist
University of Illinois Hospital and Health Sciences System
Clinical Assistant Professor
University of Illinois Chicago College of Pharmacy
Chicago, Illinois

Lindsey P. Toman, Pharm.D., BCPS, BCTXP*

Transplant Clinical Pharmacy Specialistt
PGY2 Solid Organ Transplant Residency
Program Director
The Johns Hopkins Hospital
Baltimore, Maryland

Jennifer C. Hagopian, Pharm.D., BCPS, BCTXP

Clinical Pharmacist Specialist, Solid Organ Transplant
Michigan Medicine
Ann Arbor, Michigan

Dana Pierce, Pharm.D., BCTXP

Clinical Assistant Professor
Clinical Transplant Pharmacist
University of Illinois Chicago Retzky College of Pharmacy
Chicago, Illinois

Heart Transplantation; Lung Transplantation; Maintenance of Immunosuppression Part Two - Module 4

Faculty

Tara Veasey Rackley, Pharm.D., BCPS, BCTXP

Clinical Pharmacy Specialist, Cardiac Transplant
Allegheny General Hospital
Pittsburgh, Pennsylvania

Lisa Potter, Pharm.D., FCCP, FAST, BCTXP, BCPS*

Clinical Coordinator, Transplant Pharmacy Services
University of Chicago Medicine
Chicago, Illinois

Cassie Stromayer Muran, Pharm.D., BCPS, BCTXP

Maintenance of Immunosuppression Part Two Kidney
Abdominal Transplant Clinical Pharmacist
University of Illinois Hospital and Health Sciences System
Clinical Assistant Professor
University of Illinois Chicago College of Pharmacy
Chicago, Illinois

Lindsey P. Toman, Pharm.D., BCPS, BCTXP*

Maintenance of Immunosuppression Part Two Liver
Transplant Clinical Pharmacy Specialist
PGY2 Solid Organ Transplant Residency Program Director
The Johns Hopkins Hospital
Baltimore, Maryland

Lisa Potter, Pharm.D., FCCP, FAST, BCTXP, BCPS*

Maintenance of Immunosuppression Part Two Lung
Clinical Coordinator, Transplant Pharmacy Services
University of Chicago Medicine
Chicago, Illinois

Jennifer C. Hagopian, Pharm.D., BCPS, BCTXP

Maintenance of Immunosuppression Part Two Pancreas and Islet Cell
Clinical Pharmacist Specialist, Solid Organ Transplant
Michigan Medicine
Ann Arbor, Michigan

Tara Veasey Rackley, Pharm.D., BCPS, BCTXP

Maintenance of Immunosuppression Part Two Heart
Clinical Pharmacy Specialist, Cardiac Transplant
Allegheny General Hospital
Pittsburgh, Pennsylvania

Infection Prevention and Management in Solid Organ Transplant Patients; Prevention and Management of Malignancy in Solid Organ Transplant Patients - Module 5

Faculty

Hanna L. Kleiboeker, Pharm.D., BCTXP

Clinical Pharmacist, Solid Organ Transplant
University of Wisconsin Hospital and Clinics
Madison, Wisconsin

Jillian P. Casale, Pharm.D., BCTXP

Medication Safety Manager
RWJ Barnabas Health
West Orange, New Jersey

Primary Care of the Solid Organ Transplant Patient; Special Considerations in Pediatric and Geriatric Transplant Populations - Module 6

Faculty

Clare Kane, Pharm.D., BCTXP

Clinical Pharmacist, Solid Organ Transplant
Northwestern Memorial Hospital
Chicago, Illinois

Kari Allan, Pharm.D., BCPPS, BCPS

Clinical Pharmacist Specialist, Solid Organ Transplant
Department of Pharmacy
Children’s Hospital Colorado
Aurora, Colorado

Sarah E. Bova, Pharm.D., BCPS, BCTXP

Cardio-Renal Medical Science Liaison
Boehringer Ingelheim
Baltimore, Maryland

Trial Design and Biostatistics - Module 7

Faculty

Brandi L. Bowers, Pharm.D., BCACP

Clinical Associate Professor
University of Missouri-Kansas City
Springfield, Missouri

Continuity of Care and Managing Transitions of Care in the Transplant Patient/Transplant Regulations and Performance Improvement/Transplant Resources, Patient Education and Transplant Study Endpoints - Module 8

Faculty

Nicole R. Alvey, Pharm.D., FAST, BCPS, BCTXP

Associate Professor of Clinical Sciences
Roosevelt University College of Science, Health, and Pharmacy
Clinical Pharmacy Specialist, Solid Organ Transplant
Rush University Medical Center
Chicago, Illinois

Debbie Ramirez, Pharm.D., BCTXP, BCPS

Clinical Pharmacist, Value Based Care
Kidneylink
Plano, Texas

Tiffany E. Kaiser, Pharm.D., MS, FCCP, AF-AASLD

Transplant Clinical Pharmacist
Director, Solid Organ Transplant Quality
University of Cincinnati
Cincinnati, Ohio

CPE Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Target Audience: Solid Organ Transplantation Pharmacy Preparatory Review and Recertification Course is designed to help pharmacists who are preparing for the Board of Pharmacy Specialties certification examination in Solid Organ Transplantation Pharmacy, those seeking BCTXP recertification credit, and those seeking a general review and refresher on disease states and therapeutics.

Contents

Transplant Immunology; Induction and Management of Acute Cellular Rejection - Module 1

Activity Number: 0217-9999-25-167-H01-P
Contact Hour(s): 2.25
Activity Type: Application Based
Learning Objectives

Transplant Immunology

  1. Differentiate between components of innate and adaptive immunity.
  2. Review lymphocyte activation, differentiation and effect mechanisms.
  3. Discuss pathways of allorecognition, transplant rejection and injury.
  4. Assess immunologic risk of rejection.
  5. Describe pathways to immunologic tolerance of allograft

Induction and Management of Acute Cellular Rejection

  1. Outline the principles of induction immunosuppression and how these agents can be used for different organs.
  2. Compare and contrast the available induction agents; specifically focusing on mechanism of action, ease of administration, adverse events and economic impact.
  3. Evaluate the efficacy of induction therapy among the different organs.
  4. Design an evidence-based induction regimen centered on donor, recipient and transplant characteristics.
  5. Compare and contrast the agents available for the treatment of acute cellular rejection.
  6. Assess the optimal therapeutic options for management of acute cellular rejection.

Maintenance of Immunosuppression Part One; Approaches to Prevent and Manage Antibody Development - Module 2

Activity Number: 0217-9999-25-168-H01-P
Contact Hour(s): 2.50
Activity Type: Application Based
Learning Objectives

Maintenance of Immunosuppression Part One

  1. Differentiate between the pharmacokinetic profiles of immunosuppressive medication formulations utilized in solid organ transplantation.
  2. Select the appropriate method for therapeutic drug monitoring of immunosuppressive medications.
  3. Design an initial immunosuppression regimen for a solid organ transplant recipient utilizing a patient’s pharmacogenomic data.
  4. Revise an immunosuppression regimen for a solid organ transplant recipient based on the presence of pertinent drug-drug interactions.
  5. Assess patient-specific data to identify immunosuppression-related adverse effects.
  6. Design an appropriate monitoring plan for immunosuppressive medications.

Approaches to Prevent and Manage Antibody Development

  1. Distinguish the role of patient characteristics, and pharmacotherapy on immunologic risk.
  2. Assess current interventions for immunologic event monitoring.
  3. Differentiate current evidence-based desensitization regimens with a focus on optimal patient selection.
  4. Compare methods of pharmacologic immunosuppression management of failed allografts.

Kidney Transplantation; Liver Transplantation; Pancreas and Islet Cell Transplantation and Intestinal Transplantation - Module 3

Activity Number: 0217-9999-25-169-H01-P
Contact Hour(s): 3.50
Activity Type: Application Based
Learning Objectives

Kidney Transplantation

  1. Assess non-pharmacologic and pharmacologic risks of patients undergoing kidney transplant evaluation.
  2. Evaluate effects of nonadherence on long-term allograft survival.
  3. Distinguish between absolute and relative contraindications to kidney transplant.
  4. Differentiate pathophysiology of and design management strategies for allograft specific complications.
  5. Design modifications to therapy that account for patient-specific factors, immunologic risk, and complications after kidney transplant.
  6. Assess barriers after kidney transplant and implement strategies to improve adherence.

Liver Transplantation

  1. Describe diagnoses that may lead to referral for liver transplantation.
  2. Identify indications and contraindications for liver transplantation.
  3. Create a medication regimen for a liver transplant recipient taking into account immunologic risks and comorbid conditions.
  4. Summarize the presentation and management of common immunologic and non-immunologic complications after liver transplantation.
  5. Evaluate potential causes of medication non-adherence after liver transplantation.

Pancreas and Islet Cell Transplantation and Intestinal Transplantation

Pancreas and Islet Cell Transplantation

  1. Demonstrate an understanding for common complications of pancreas transplantation and develop strategies to prevent or treat these complications.
  2. Devise a monitoring strategy to evaluate exocrine and endocrine function after pancreas transplantation.
  3. Compare and contrast the advantages and disadvantages of pancreas and islet cell transplantation.

Intestinal Transplantation

  1. Describe the etiologies of intestinal transplantation.
  2. List the current trends in immunosuppression for small bowel transplantation.
  3. Discuss the common complications observed after small bowel transplantation.

Heart Transplantation; Lung Transplantation; Maintenance of Immunosuppression Part Two - Module 4

Activity Number: 0217-9999-25-170-H01-P
Contact Hour(s): 4.50
Activity Type: Application Based
Learning Objectives

Heart Transplantation

  1. Describe common indications that may lead to heart transplantation.
  2. Identify pre-transplant risk factors that may impact outcomes after heart transplantation.
  3. Describe heart techniques for rejection surveillance.
  4. Understand heart specific pathologic findings.
  5. List and discuss heart specific post-transplant complications and strategies for management.

Lung Transplantation

  1. Describe diagnoses that may lead to end-stage lung disease and referral for lung transplantation.
  2. Identify indications, absolute contraindications, and relative contraindications for lung transplantation.
  3. Formulate a medication regimen for a lung transplant recipient, taking into account immunologic risks and needs, preventative needs, and comorbid diseases.
  4. Explain the objective testing used to evaluate lung allograft function.
  5. Summarize the presentation and management of common immunologic complications after lung transplantation.
  6. Summarize the presentation and management of common non-immunologic complications after lung transplantation.

Maintenance of Immunosuppression Part Two

Kidney

  1. Create an evidence-based maintenance regimen for a kidney transplant recipient that accounts for patient-specific factors.
  2. Evaluate the role of extended-release tacrolimus formulations and novel immunosuppression regimens. 

Liver

  1. Evaluate maintenance immunosuppression regimens for liver transplant recipients that account for patient-specific factors.
  2. Design evidence based maintenance immunosuppression regimens for liver transplant recipients.

Lung

  1. Compare and contrast the benefit, risk, and role of each maintenance immunosuppressant medication in lung transplantation.
  2. Design evidence-based maintenance immunosuppression regimens for lung transplant recipients.

Pancreas and Islet Cell

  1. Design a maintenance immunosuppression regimen for the prevention of rejection after pancreas transplant.
  2. Design a maintenance immunosuppression regimen for the prevention of rejection after islet cell transplant.

Heart

  1. Describe common immunosuppression approaches in heart transplantation.
  2. Discuss alternate approaches to immunosuppression.

Infection Prevention and Management in Solid Organ Transplant Patients; Prevention and Management of Malignancy in Solid Organ Transplant Patients - Module 5

Activity Number: 0217-9999-25-171-H01-P
Contact Hour(s): 2.50
Activity Type: Application Based
Learning Objectives

Infection Prevention and Management in Solid Organ Transplant Patients

  1. Develop appropriate pre-transplant serologic testing recommendations and interpretation of these results.
  2. Identify risk factors associated with post-transplant infections and the epidemiology and timing of these infections.
  3. Design strategies to prevent post-transplant opportunistic infections, including prophylaxis regimens and monitoring parameters.
  4. Formulate treatment plans for bacterial, viral, and fungal infections in solid-organ transplant recipients.
  5. Develop monitoring plans for patients receiving antimicrobials, complete with management of adverse effects and intolerances.

Prevention and Management of Malignancy in Solid Organ Transplant Patients

  1. Demonstrate the common pathogenesis of and risk factors for types of malignancy after solid organ transplant.
  2. Distinguish between the types of malignancy that are of increased risk before and after solid organ transplant.
  3. Assess preventative strategies for malignancy after transplantation.
  4. Diagram an overview of immunosuppression management in the setting of malignancy.
  5. Compare common treatment approaches to common malignancies after transplantation, including non-melanoma skin cancer, post-transplant lymphoproliferative disorder, and Kaposi’s sarcoma.

 

Primary Care of the Solid Organ Transplant Patient; Special Considerations in Pediatric and Geriatric Transplant Populations - Module 6

Activity Number: 0217-9999-25-172-H01-P
Contact Hour(s): 3.00
Activity Type: Application Based
Learning Objectives

Primary Care of the Solid Organ Transplant Patient

  1. Apply general principles and practices of disease prevention to solid organ transplant recipients.
  2. Outline unique patient populations that require additional disease screening.
  3. Create an immunization plan for a solid organ transplant recipient in both the pre and post-transplant setting.
  4. Identify reputable resources for public education and awareness on organ transplantation including organ donation

Special Considerations in Pediatric and Geriatric Transplant Populations

Pediatrics

  1. Discuss practical differences of medication use in children with emphasis on pharmacokinetics, formulations, and monitoring of commonly used immunosuppressants.
  2. Describe the etiologic differences for organ disease and discuss associated complications after solid organ transplant in children.
  3. Design a pharmacotherapeutic treatment plan for pediatric patients undergoing intended ABO incompatible organ transplantation.
  4. Formulate an immunization plan for a pediatric organ transplant candidate.

Geriatrics

  1. Compare outcomes of transplant recipients by age group.
  2. Evaluate geriatric candidates for transplant based on guideline recommendations.
  3. Distinguish pharmacokinetic differences among geriatric transplant recipients.
  4. Design an immunosuppression regimen for a geriatric transplant recipient.

Trial Design and Biostatistics - Module 7

Activity Number: 0217-9999-25-173-H99-P
Contact Hour(s): 2.50
Activity Type: Application Based
Learning Objectives

Trial Design and Biostatistics

  1. Describe hypothesis testing and state the meaning of and distinguish between p values, confidence intervals, and measures of central tendency and data spread.
  2. Define, compare, and contrast the concepts of internal and external validity, causation, association, bias, confounding, subgroup analysis, surrogate endpoints, and composite endpoints in trial design.
  3. Compare and contrast the advantages and disadvantages of various study designs (e.g., prospective, retrospective, case-control, cohort, cross-sectional, randomized controlled clinical trials, systematic review, and meta-analysis).
  4. Determine why a statistical test is appropriate or not appropriate, given the sample distribution, data type, and study design.
  5. Interpret statistical and clinical significance for results from commonly used biostatistical estimation strategies (i.e., confidence intervals) and statistical tests (i.e., p-values).
  6. Define and evaluate odds ratio, risk/incidence rate, relative risk, number needed to treat, number needed to harm, and other risk estimates.

Continuity of Care and Managing Transitions of Care in the Transplant Patient/Transplant Regulations and Performance Improvement/Transplant Resources, Patient Education and Transplant Study Endpoints - Module 8

Activity Number: 0217-9999-25-174-H99-P
Contact Hour(s): 3.75
Activity Type: Application Based
Learning Objectives

Continuity of Care and Managing Transitions of Care in the Transplant Patient

  1. Describe the role of the pharmacist in obtaining an accurate medication, allergy and immunization history and the importance of proper medication reconciliation in solid organ transplant recipients at all stages of the transplant process.
  2. Identify challenges in assessing readiness of a pediatric patient to transition to the adult transplant care team.
  3. Examine the unique role of a pharmacist in the transition of solid organ transplant recipients between healthcare settings as it relates to medication error reduction, cost avoidance, and hospital readmission.
  4. Summarize the common obstacles and potential solutions to proper medication adherence post-transplant including health literacy, cultural competence and language and sensory barriers.
  5. Identify common barriers to medication access in solid organ transplant recipients and compare the various medication access resources available.

Transplant Regulations and Performance Improvement

  1. Review regulations for solid organ transplantation (SOT) programs.       
  2. Highlight regulations that may involve SOT pharmacists.                             
  3. Discuss strategies to develop policies and procedures for SOT pharmacists that are consistent with transplant regulatory requirements.            
  4. Identify opportunities for SOT pharmacists to participate in Quality Assessment and Performance Improvement (QAPI) activities to enhance the safety and effectiveness of medication-use process in SOT.                                  
  5. Diagram involvement of SOT pharmacists in collaborative relationships with interdisciplinary transplant team to promote quality patient care across the continuum.

Transplant Resources, Patient Education and Transplant Study Endpoints

  1. List key government organizations and transplant societies that influence the practice of solid organ transplantation.
  2. Compare practice-defining guidelines within the field of solid organ transplantation.
  3. Assess patients’ barriers to understanding their medication regimen and adapt education strategy to foster patient competency.
  4. Describe appropriate monitoring strategies for transplant medications requiring REMS participation.
  5. Formulate an appropriate contraceptive regimen for a female transplant recipient of childbearing age.
  6. Evaluate patient risk factors for non-adherence and implement a plan to improve compliance.
  7. Review transplant study end points used in the literature to establish efficacy of clinical intervention.

Commercial Support

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.